Fenofibric acid: A new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 351-362

  Alagona Jr , Peter ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Dyslipidemia; Fenofibric acid; Fibrate; Non high density lipoprotein; Peroxisome proliferated activated receptors; Triglycerides; TriLipix; Very low density lipoprotein

Indexed keywords

A 52799; A 770335; A 770335 115; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; CHOLINE FENOFIBRATE; CIPROFIBRATE; CLOFIBRATE; COLESEVELAM; EZETIMIBE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; FENOFIBRATE; LIPID; LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; MICROALBUMINURIA; MONOTHERAPY; MORTALITY; MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; REVIEW; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DELAYED RELEASE FORMULATION; DRUG APPROVAL; DRUG COMBINATION; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG APPROVAL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIPOPROTEINS; PROCETOFEN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77955909914     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s6714     Document Type: Review

References (69)

1. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA. 1986;256:2835-2838.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
4. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl JMed. 2004;350:1495-1504.
5. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
6. Pedersen TR, Faergeman O, Kastelein JJ, et al. High dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
7. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
8. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation. 1998;97:1436-1439.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
10. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
11. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145:520-530.
12. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832-1844.
13. Koschinsky ML, Marcovina SM. In: Ballantyne, CM, editor. Clinical Lipidology: A Companion to Braunwald's Heart Disease. Philadelphia: Saunders Elsevier; 2009:130-143.
14. Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin Cornerstone. 2006;8 Suppl 1:S21-S27.
15. Castelli WP. Cholesterol and lipids in the risk of coronary heart disease-the Framingham Heart Study. Can J Cardiol. 1988;4 Suppl A:5A-10A.
16. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992;70:3H-9H.
17. Gordon DJ, Probstfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15.
18. Hokanson JE and Austin MA. Triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
19. Yarnell JWG, Patterson CC, Sweetnam PM, et al. Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease. Arterioscler Thromb Vasc Biol. 2001;21:1340-1345.
20. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Clinical investigation and reports: Triglyceride concentration and ischemia heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
21. Assmann G, Schulte H and Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179-1184.
22. Genest JJ, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
23. Genest JJ, McNamara JR, Salem DN, Shaefer, EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991;67:1185-1189.
24. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
25. Liu J, Sempos CT, Donahue RP, et al. Non-high density lipoprotein and very low density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98: 1363-1368.
26. Frick MH, Elo MO, Happa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
27. Haim M, Benderly M, Brunner D, et al. Elevated serum triglyceride levels in patients with coronary heart disease: The bezafibrate Infarction Prevention (BIP) Registry. Circulation. 1999;100:475-482.
28. Carlson LA, Rosenhaner G. Reduction of mortality in the in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
29. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low high-density cholesterol. N Engl J Med. 1999;341:410-418.
30. Keech A, Simes RJ, Barter P, et al. The Field Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised control trial. Lancet. 2005;366:1849-1861.
31. The "Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus" an NIH study with support from multiple industry partners was just published (Effects of Combination Therapy in Type 2 Diabetes Mellitus. The ACCORD Study Group. N Engl J of Med; March 14, 2010, and updated on March 18, 2010, at NEJM.org (10.1056/NEJMoa1001282).
32. Superko HR, King S III. Is lowering low-density lipoprotein an effective strategy to reduce cardiac risk. Circulation. 2008;117:560-568.
33. Staelas B, Dallongville J, Auwerx J, et al. Mechanism of action of f ibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
34. Berger J, Moeller D. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435.
35. Staels B, Auwerx J. Regulation of apoA-1 gene expression by fibrates. Atherosclerosis. 1998; Suppl 137:S19-S23.
36. Chinetti G, Lastavel S, Bocker V, et al. PPAR-alpha and PPAR gamma activators induce cholesterol removal from human macrophages from cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58.
37. Marx N, Sukhova GK, Collins T, et al. PPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125-3131.
38. Marx N, Mackman N, Schonbeck U, et al. PPAR alpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001;103:213-219.
39. Jones, PH. Fibrates. In: Ballantyne, CM, editor. Clinical Lipidology: A Companion to Braunwald's Heart Disease. Philadelphia: Saunders Elsevier; 2009:315-325.
40. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, f ibrate and combination therapy among diabetic patients with mixed dyslipidemia. The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006;48:396-401.
41. Koh KK, Han SH, Quon MJ, et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care. 2005;28:1419-1424.
42. Wysocki J, Belowski D, Kalina M, et al. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther. 2004;42:212-217.
43. Ellen RLB, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combination hyperlipidemia. Am J Cardiol. 1998;81(4A):60B-65B.
44. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The Safari Trial). Am J Cardiol. 2005;95:462-468.
45. Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol. 2007; Suppl 99:3C-18C.
46. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005;26:897-905.
47. Farnier M, Roth E, Gil-Extremera B, et al. Efficacy and safety of the coadministration ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J. 2007;153:335.e1-335.e8.
48. Rizos E, Biaraktari E, Ganotakis E, et al. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther. 2002;7:219-226.
49. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events 9795 people with type II diabetes mellitus (the FIELD study): Randomized control trial. Lancet. 2005;366:1849-1861.
50. Hottelart C, El Esper N, Rose F, et al. Fenofibrate increased creatinemia by increasing metabolic production of creatinine. Nephron. 2002;92:536.
51. Tsimihodimos V, Miltiadous G, Bairaktari E and Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol. 2002;57:407-408.
52. Tonelli M, Collins D, Robins S, et al. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis. 2004;44:832-839.
53. Ansquen JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in Type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45:485-493.
54. Mekkies M, Stein E, Khoury P, et al. Effects of fenofibrate on lipids, lipoproteins and apolipoproteins in 33 subjects with primary hypercholesterolaemia. Atherosclerosis. 1987;63:57-64.
55. Bradford R, Goldberg A, Schoenfeld G, et al. Double-blind comparison of bezaf ibrate versus placebo in male vol -unteers with hyperlipoproteinemia. Atherosclerosis. 1992;92: 31-40.
56. Gotto AM, Breen WJ, Cordner CN, et al. Once-daily, extended-release gemfibrozil in patients with dyslipidemia. The Lopid SR Work Group I. Am J Cardiol. 1993;71:1057-1063.
57. Zimetbaum P, Frishman WH, Kahn S. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J Clin Pharmacol. 1991;31:25-37.
58. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of f ibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
59. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, et al. Effects of gemfibrozil on low-density lipoprotein particle size, density, distribution and composition in patients with type II diabetes. Diabetes Care. 1993;16:584-592.
60. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol. 2005;45:1649-1953.
61. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin. 2005;21:1403-1412.
62. Trilipix [package insert]. North Chicago (IL): Abbott Laboratories; 2008.
63. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate +fibrates versus gemfibrozil +any statin. Am J Cardiol. 2005;95:120-122.
64. Jones PH, Bays HE, Davidson MH, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins. Clin Drug Investig. 2008;28:625-634.
65. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis. 2009;204:208-215.
66. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 fenofibric acid in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, control study. Am Heart J. 2009;157:195-203.
67. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009;103:515-522.
68. Bays HE, Jones PH, Mohiuddin SM, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol. 2008;2:426-435.
69. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811-822.